论文部分内容阅读
近日,西雅图癌症治疗联盟的科学家们研究表示,当前列腺癌个体正在进行去势治疗时,如果服用他汀类药物或可有效减缓患者前列腺癌的病情恶化。研究者表示,从患者开始进行去势治疗就开始服用他汀类药物,那么在疾病恶化前患者平均会存活27.5个月,而不服用他汀类药物的患者仅会生存17.4个月;该研究中包括926例患者。Lauren Harshman博士表示,他汀类药物服用使得患者延长了10个月的寿命,这就表明他汀类药物或许是当前前列腺癌疗法最有价值的辅助治疗手段;而相关的研究结果也被多种此前的流行病学研究所证实,
Recently, Seattle Cancer Research Alliance scientists said that when individuals with prostate cancer undergoing ovariectomy, if taking statins or can effectively reduce the patient’s condition of prostate cancer worsened. The researchers said that starting statin therapy started with patients who started on castration and then survived for an average of 27.5 months before disease progression and only 17.4 months for those not taking statins; the study included 926 patients. Lauren Harshman, Ph.D., said statin use prolongs the patient’s lifespan by 10 months, suggesting that statins may be the most valuable adjuvant treatment for prostate cancer therapies, and the results of the study have also been a variety of previous Confirmed by the Institute of Epidemiology,